Two Sigma Investments
ENGN icon

Two Sigma Investments’s enGene Therapeutics ENGN Stock Holding History

Two Sigma Investments’s Portfolio ENGN Stock Details ENGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.08M Sell
159,069
-2,443
-2% -$21.7K ﹤0.01% 3208
2025
Q4 		$1.46M Buy
+161,512
New +$1.29M ﹤0.01% 2682
2025
Q2 		– Sell
-15,832
Closed -$70.9K – 3261
2025
Q1 		$70.9K Sell
15,832
-20,034
-56% -$124K ﹤0.01% 3003
2024
Q4 		$239K Sell
35,866
-3,755
-9% -$29.2K ﹤0.01% 2816
2024
Q3 		$261K Buy
+39,621
New +$295K ﹤0.01% 2729

Other funds holding ENGN

FIS
FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return

Two Sigma Investments's ENGN Position: Q1 2026 in Review

Two Sigma Investments reduced its enGene Therapeutics (ENGN) stake by 1.5% in Q1 2026, selling an estimated $21.7K and leaving 159,069 shares worth $1.08M. The position accounts for ﹤0.01% of the portfolio, ranked #3208.

Two Sigma Investments first reported a position in ENGN in Q3 2024 and has held it in 5 quarters since. The position peaked at $1.46M in Q4 2025. 61 funds tracked by Wall St. Rank hold ENGN as of Q1 2026.

  • Two Sigma Investments held 159,069 shares of enGene Therapeutics worth $1.08M as of Q1 2026.
  • Two Sigma Investments sold 2,443 enGene Therapeutics shares in Q1 2026, an estimated $21.7K.
  • enGene Therapeutics made up ﹤0.01% of Two Sigma Investments's portfolio in Q1 2026, its #3208 holding.
  • Two Sigma Investments first reported a position in enGene Therapeutics in Q3 2024 and has held it in 5 quarters since.
  • Two Sigma Investments's enGene Therapeutics position peaked at $1.46M in Q4 2025.
  • 61 funds tracked by Wall St. Rank held enGene Therapeutics as of Q1 2026.

Based on Two Sigma Investments's 13F filing for Q1 2026, filed 15 May 2026.